Gerard Sanacora, MD, PhD
Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
Original Research
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
May 4, 2026
In patients with major depression and suicidal ideation, adding a 16-week CBT course to esketamine led to greater improvements in suicidal ideation and depression severity than esketamine alone.
Original Research
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
September 3, 2025
Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
Original Research
Effect of Benzodiazepines on Antidepressant Effects of Ketamine
November 14, 2022
Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...
Original Research
Ketamine as a Clinical Treatment for Mood Disorders
July 24, 2018
Ketamine, an off-label treatment for depression, can have rapid-acting antidepressant effects but is also sometimes associated with negative clinical outcomes. Do the short- and long-term benefits of ketamine treatment...
